Tazemetostat is currently in phase 2 clinical trials in combination with the PD-1 inhibitor TecentriqTM (atezolizumab) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and thus future combination studies will need to address whether EZH2 inhibitors or other epigenetic drugs can reduce EMT and increase response to ICB in pancreatic cancer or other solid cancers. Here, EZH2 is linked to diffuse large B-cell lymphoma.